Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

The EU is contributing €9 million to the “Vigilance against Viral Resistance” (VIRGIL) project

Viruses’ growing resistance to drugs means diseases such as hepatitis B and C are increasingly difficult to treat. New pandemics may arise with unforeseeable consequences.

29 Jun 2004

Smoking a lot more harmful than previously thought

The U.S. Surgeon General has released a new comprehensive report on smoking and health, revealing for the first time that smoking causes diseases in nearly every organ of the body. Published 40 years after the surgeon general's first report on smoking -- which concluded that smoking was a definite cause of three serious diseases -- this newest report finds that cigarette smoking is conclusively linked to diseases such as leukemia, cataracts, pneumonia and cancers of the cervix, kidney, pancreas and stomach.

30 May 2004

Smoking causes diseases in nearly every organ of the body

U.S. Surgeon General Richard H. Carmona today released a new comprehensive report on smoking and health, revealing for the first time that smoking causes diseases in nearly every organ of the body.

27 May 2004

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Results of a new study published in the current issue of the New England Journal of Medicine show that in patients who have chronic hepatitis C, genotype 1 -- the most common form of the disease and difficult to treat successfully -- non-Hispanic whites achieved one of the highest response rates reported to date, but response rates in African Americans were significantly lower.

27 May 2004

Causes of hepatitis and potential therapies that may improve care presented in study

Hepatitis, a potentially serious disease caused by a virus that attacks the liver, is a major problem worldwide. Hepatitis A is generally food-borne, while hepatitis B and C spread primarily through parenteral or sexual routes. Hepatitis B and C can be life-long, potentially deadly chronic infections.

19 May 2004

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Benitec Ltd. today announced the acquisition of Avocel, Inc. of Sunnyvale, CA, a leading RNAi therapeutics company, and the establishment of its wholly-owned US subsidiary, Benitec, Inc. Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the Hepatitis C virus.

18 May 2004

Australian company receives FDA orphan drug designation for product to treat malignant melanomas

Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma.

3 May 2004

Hepatitis B vaccination for inmates

rrectional settings provide a unique opportunity to offer hepatitis B vaccination to a substantial number of high-risk adults who are willing to be vaccinated and who would not otherwise have access to the preventive medicine, according to a new Brown University study of inmates within the Rhode Island Department of Corrections.

23 Apr 2004

Link between iron regulation and the immune system

Patients with chronic inflammatory disorders, including infections, inflammatory bowel disease, arthritis and cancer, commonly become anemic. The anemia can make them sicker, is sometimes severe enough to require a blood transfusion, and responds only partially to current treatments.

20 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Mayo Clinic debunks myths cancer myths

Believing cancer myths can be dangerous to your health, because they could prevent you from having the tests and treatments needed to detect and treat cancer.

16 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

Haemophilia Society President presents Hepatitis C (HCV) Facts to UK Government

Haemophilia Society President to challenge government for second time in Lords question on proposed Hepatitis C ex gratia payment scheme On Thursday 25 March, the first business in the House of Lords will be further questioning of Ministers by the Haemophilia Society’s President, Lord Morris of Manchester.

27 Mar 2004

Tiny Ribozyme package could be future treatment of Hepatitis B virus

Penn State College of Medicine researchers have developed a tiny package that searches for and destroys up to 80 percent of hepatitis B virus in the livers of mice.

22 Mar 2004